Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.

Publikation

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.

Wissenschaftlicher Artikel/Review - 10.06.2022

Dafni U, Soo R A, Peters S, Tsourti Zoi, Zygoura P, Vervita K, Han J-Y, de Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A

Zitation

Dafni U, Soo R, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J, de Castro J, Coate L, Früh M, Hashemi S, Nadal E, Carcereny E, Sala M, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022; 7:100507.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

ESMO Open 2022; 7

Veröffentlichungsdatum

10.06.2022

eISSN (Online)

2059-7029

Seiten

100507

Kurzbeschreibung/Zielsetzung

The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in patients with a smoking history and prompted us to do this study.